and other degenerative conditions, 2 suggesting the potential of ferrostatins as therapeutic agents. Significant exploration of the structure-activity relationship (SAR) of ferrostatins has led to analogs with increased potency and metabolic stability; 2, 4, 7 even so, many aspects of the mechanism of ferroptosis itself, and its suppression by ferrostatins remain to be elucidated.
The correlation between increased lipophilicity and increased potency was one of the first trends discovered in exploring the SAR of ferrostatins. Increasing the lipophilicity of the hydrocarbon moiety on either one of the arylamines led to ferrostatins with greater potency. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 6 alkynes, conjugated alkynes (e.g., a diyne) further enhance the SRS signal, allowing higher detection sensitivity and lower concentrations of the probe compound.
11, 12
Given these considerations, we designed and synthesized diyne ferrostatin analog 2 ( Figure 1A) . Because of the functional tolerance of ferrostatins to extensive substitution at the 4 position, 2 we hypothesized that incorporation of a diyne moiety at this position would not significantly alter the potency of compound 2 relative to the parent ferrostatin-1. To maintain the lipophilicity required for anti-ferroptotic activity, the diyne moiety of 2 was capped with a highly lipophilic n-butyl group. The calculated octanol/water partition coefficient (cLogP) of compound 2 was 3.78, making it slightly more lipophilic than ferrostatin-1 (cLogP 3.2). 2 To validate the potency and activity of compound 2,
we treated ferroptosis-sensitive HT-1080 fibrosarcoma cells with a lethal dose of the ferroptosis inducer erastin, and a serial dilution of ferrostatin-1 or compound 2 ( Figure 1B ). We found that compound 2 suppressed ferroptosis with a potency similar to ferrostatin-1, confirming that the diyne tag did not significantly affect the anti-ferroptotic activity of the original compound.
Having verified the anti-ferroptotic activity of probe 2, we aimed to image its distribution in living cells. First, we confirmed that the diyne tag of probe 2 shows a distinct peak at 2262 cm -1 within the cell Raman-silent window (Supplemental figure 1) . Next, HT-1080 cells were treated with 2 and erastin simultaneously, and imaged by SRS microscopy after 6 h of incubation ( Figure 1C We sought to determine if this observed distribution was due to accumulation of probe 2 at specific organelles. We hypothesized that the large puncta might correspond to accumulation within lysosomes. HT-1080 cells were treated with probe 2 for 6 h, followed by 30 min with the lysosome-targeted fluorescent dye LysoTracker, and both compounds were imaged within the same cells by correlative SRS and fluorescence microscopy ( Figure 1E ). The LysoTracker signal showed partial overlap with the large puncta from probe 2, suggesting that these sites of ferrostatin accumulation were indeed lysosomes. 8
In addition to lysosomes, the mitochondria and endoplasmic reticulum (ER) have also been hypothesized to play roles in ferroptosis, 1, 13 and were additional sites of localization of probe 2. We therefore sought to examine whether probe 2 accumulated at either of these organelles. HT-1080 cells were treated with 2 and both a mitochondria-specific and ER-specific fluorescent dye ( Figure 1F ). Though the lower signal intensity of 2 at these sites indicated that 2 was present at lower concentrations in both of these locations than in lysosomes, 2 showed a clear pattern of overlap with the mitochondria-specific fluorescent dye Mito Tracker
Deep Red. Due to the diffuse nature of ER network, it was unclear if the widespread distribution of 2 was due to specific accumulation within ER, but the image we observed was nonetheless consistent with ER accumulation of ferrostatins, given that it was not as diffuse at the extent of cytosol. Thus, based on the linear concentration dependence of SRS signal, we concluded that 2 accumulates primarily in lysosomes, with additional localization in mitochondria and ER, but did not show detectable concentrations in the plasma membrane or the nucleus.
Accumulation at Lysosomes Reduces the Potency of Ferrostatins
The role of lysosomes in ferroptosis is unclear. Earlier studies reported a burst of reactive oxygen species (ROS) in lysosomes of cells undergoing ferroptosis, 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 lysosomes store iron imported by endocytosis of transferrin, a process critical for ferroptosis. 15 Correspondingly, the membrane-impermeable iron chelator DFO likely protects against ferroptosis by chelating iron accumulated in lysosomes via endocytosis.
16
We hypothesized that ferrostatins accumulate in lysosomes because of the lysosomotropic effect. 17 In their neutral form, small molecules with weakly basic sites (generally aromatic or aliphatic amines) can freely diffuse through lipid membranes and between cellular compartments. In acidic lysosomes (pH 4.5-5.0), basic groups are protonated and unable to diffuse out because of the resulting positive charge. In this way, molecules can be trapped in lysosomes, even if their biological target is elsewhere in a cell. 18 In support of our hypothesis, we calculated the acidity of the conjugate acids of each amine on ferrostatin-1 in an aqueous environment. We found that the conjugate acid of the unsubstituted arylamine has a pK a of 4.6, suggesting it can be protonated in the lysosome.
Given the basic aromatic amines in ferrostatins and the observed high levels of accumulation of probe 2 within lysosomes, we examined whether lysosomal accumulation of ferrostatins was critical to their mechanism of ferroptosis rescue or if lysosomotropism prevents ferrostatins from reaching their necessary targets.
We first incubated HT-1080 cells with a lethal dose of erastin and a serial dilution of ferrostatin-1, as well as 0 (vehicle only), 5, or 10 µM chloroquine ( Figure 2A ).
Chloroquine is a classic lysosomotropic agent, and is protonated in lysosomes, 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 thus raising lysosomal pH, reducing the extent of molecular trapping by the lysosomotropic effect for other compounds. We found that co-treatment of cells with ferrostatin-1 and chloroquine caused an increase in the potency (lower EC 50 )
of ferrostatin-1 in a chloroquine dose-dependent manner (Figure 2A ).
Since preventing ferrostatin accumulation in lysosomes increased ferrostatin potency (Figure 2A ), we hypothesized that promoting ferrostatin accumulation in lysosomes would correspondingly decrease their potency (i.e., require a higher concentration of ferrostatin to suppress ferroptosis). We designed and synthesized ferrostatins 3 and 4, which each contain a basic morpholine group, a moiety commonly used to target molecules to lysosomes ( Figure 2B 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 11 sequestration in lysosomes. Cumulatively, these data suggest that reducing the basicity of the ferrostatin amines could improve potency by reducing lysosomal sequestration, although a careful balance between basicity and reduction potential of amines needs to be considered for developing more effective ferroptosis inhibitors. With the ability to perform direct SRS imaging of drug distribution inside cells, this methodology is an example of exploring the structure-distribution-activity relationship, and correlating this with the structureactivity relationship.
Mitochondria are not required for ferroptosis or ferroptosis rescue by ferrostatin-1
Since ferrostatin analog 2 showed accumulation in mitochondria, we sought to determine whether mitochondria are necessary for ferroptosis, as well as for ferroptosis rescue by ferrostatins. ROS generated by the mitochondrial electron transport chain do not contribute to ferroptosis, as cells lacking mitochondrial DNA are still sensitive to ferroptosis. 1 Still, ACSL4-dependent alterations in mitochondrial morphology are observed in cells undergoing ferroptosis, 1, 20, 21 and the nitroxide antioxidant XJB-5-131, which is targeted to mitochondria, is a more potent inhibitor of ferroptosis than untargeted analogs.
22
To examine the necessity of mitochondria for ferroptosis, we generated mitochondria-deficient cells, using a previously reported mitophagy protocol.
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The E3 ligase parkin causes the elimination of mitochondria lacking a membrane 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 potential via mitophagy, a macroautophagic process specific to mitochondria.
23, 24
We generated stably transfected HT-1080 cells expressing YFP-parkin or mCherry-parkin ( Figure 3A) . Loss of membrane potential was induced by treatment with the uncoupling agent carbonyl cyanide m-chlorophenyl hydrazine (CCCP). Following treatment of YFP-parkin-expressing cells or mCherry-parkinexpressing cells with CCCP for 48 h, we examined the levels of the mitochondria specific proteins tom20 and cytochrome C ( Figure 3B ). Parkin-expressing cells had highly diminished levels of both proteins after 48 hours of CCCP treatment, confirming the elimination of most mitochondria. Extensive mitochondrial depletion within 48 h has been observed in other cell types using this approach. 23, 24 We also observed near-complete absence of the complex 1 genes
Mt-Nd1 and Mt-Nd2 following CCCP treatment ( Figure 3C and 3D) . YFP-parkin CCCP-treated cells also showed a decrease in immunofluorescence signal when imaged for mitochondria-specific proteins COX IV and HSP60, while wild-type cells showed no significant change (supplemental figure 3A) . Electron microscopy imaging of YFP-parkin-expressing cells treated with CCCP confirmed a significant decrease in the number of observable mitochondria by TEM ( Figure   3E and supplemental figure 3B ). YPF-parkin cells depleted of mitochondria also showed a large increase in the abundance of endoplasmic reticulum and/or Golgi bodies (supplemental figure 3B) . Cells depleted of mitochondria showed a greatly decreased growth rate, but were nonetheless persistent in cell culture over multiple days. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 13
To examine the necessity of mitochondria for ferroptosis, we treated YFP-Parkin- figure 3D) . Additionally, wild-type HT-1080 cells treated with CCCP were still sensitive to staurosporine and showed no change in sensitivity to ferroptosis inducers, other than the modest resistance to system x c -inhibitors noted above (supplemental figure 3E ). 
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We then evaluated the ability of ferroptosis-suppressing compounds to prevent ferroptosis in cells depleted of mitochondria. Both ferrostatin-1 and iron chelators (deferoxamine and ciclopirox olamine) were able to prevent erastin-induced ferroptosis in a dose-dependent manner (supplemental figure 3F and 3G) , confirming that the mechanism of erastin lethality was consistent with ferroptosis in CCCP-treated YFP-parkin cells. We evaluated the potency of ferrostatin-1 in YFP-parkin-transfected HT-1080 cells following mitophagy ( Figure 3G ). Cells were treated with a lethal concentration of either the class 1 ferroptosis inducer erastin or the class 2 ferroptosis inducer RSL3, 16 and a serial dilution of ferrostatin-1. In both cases, ferrostatin-1 became moderately more potent following mitophagy, indicating that mitochondria are not required for ferroptosis suppression by ferrostatins.
The data above suggest that mitochondria are not necessary for ferroptosis induction and neither mitochondria nor lysosomes are necessary for ferroptosis induction or ferrostatin action, despite the prominent accumulation of ferrostatin-1 in these organelles. Together with the overall distribution of diyne ferrostatin 2 observed by SRS ( Figure 1C ), this suggests that the location in which ferrostatin exerts its anti-ferroptotic action is likely the ER, unless there is another relevant location with very low levels of ferrostatin present, below the detection limit of SRS. The hypothesis that ER is the site of ferrostatin action is supported by the increased potency of ferrostatin-1 in post-mitophagy cells, which showed greater ER abundance (supplemental figure 3B ). 
Discussion
In this study, we sought to gain insight into the mechanism of ferroptosis suppression by ferrostatin-1. The ability of ferrostatin-1 to act as a reducing agent was one of the earliest observed properties of the compound, 1 and served as the basis for initial hypotheses about its mechanism of action. To examine the role of ferrostatin localization at mitochondria, we generated a stably transfected cell line that was depleted of mitochondria. We found that mitochondria-deficient cells were still sensitive to ferroptosis, and could still be rescued by ferrostatins and iron chelators. It should be noted that a very small number of mitochondria may still remain in these cells, and we cannot yet rule and drug potency, and using this information to guide iterative rounds of structure design, we are adopting a strategy of integrating the structure-distribution-activity relationship. Such a methodology can be applied to study the mechanism of other drugs.
Together, these data suggest that ferrostatin accumulation within the endoplasmic reticulum could be critical to ferroptosis suppression, and that the ER may also be critical to ferroptosis initiation. The ER lumen is an oxidative environment and might initiate ferroptosis as a consequence of ER-related oxidative stress. Alternately, the ER is the source of lipids for most membranes in other organelles and contains more than half of all lipid bilayers in any given cell. 25 Therefore, it is possible that ferrostatin accumulation within the ER is the most efficient strategy to maintain overall peroxide tone within cellular membranes; ER localization would allow ferrostatins to prevent oxidation of the majority of cellular lipids, thereby decreasing lipid peroxide abundance. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 µL medium containing 12.5 µM CCCP and allowed to adhere for 24 additional hours (48 h CCCP treatment in total). The medium was either kept or replaced with CCCP-free medium (herein designated "+CCCP" or "+Mitophagy -CCCP", respectively), and treated with 5 µL medium containing molecules as described above. Viability was assayed using CellTiter-Glo® (Promega) according to the manufacturer's protocol. Luminesence was read on a Victor X5 plate reader and data were analyzed as described above. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   20 imaging. Fluorescence imaging is performed using the Olympus FV1200 confocal microscope with standard laser excitation and bandpass filter set for each dye.
Methods
All images are assigned color and analyzed by ImageJ. 
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